Late last week, Valneva announced the publication of new mixed data from a small exploratory study investigating the use of its inactivated Covid-19 vaccine, VLA2001, as a heterologous booster.

According to these data, a booster dose was well tolerated in participants previously vaccinated with Pfizer-BioNTech or Moderna products, confirming the favorable safety profile of VLA2001, whether with a homologous or heterologous booster.

In contrast, the French vaccine company reports that, in this study, a booster dose with its product generated only a marginal increase in neutralizing antibody response.

Valneva is currently seeking regulatory approval for VLA2001 as a homologous and heterologous booster in people previously vaccinated with AstraZeneca's ChAdOx1-S.

Copyright (c) 2023 CercleFinance.com. All rights reserved.